Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Multiple fresh catalysts: Q2 2026 revenue of $796M and adjusted EBITDA of $206M beat estimates, full-year 2026 guidance was raised again, July debt repricing lowers interest costs, and recent FDA approvals add product momentum. Stock is up about 10.5% over 21 trading days.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Margin Expansion ⢠Extreme Leverage ⢠Negative Cash Flow AMRX's improved margins and interest coverage are outweighed by negative free cash flow, shrinking cash, and extreme leverage, making the shares financially high-risk at current valuation.
Price Behavior
Key Price Behavior Insights: ⢠Trend remains weak ⢠Support approaching ⢠Rebound failed Support Level: $17.40â$17.50 Resistance Level: $17.90â$18.10 AMRX remains bearish over the last month, with support at $17.40â$17.50 offering bounce potential but downside risk persisting unless it reclaims $18.10.
Sentiment & News
Key News Insights: ⢠Kashiv acquisition ⢠Raised guidance ⢠Legal investigation Amneal's Kashiv acquisition strengthens long-term biosimilars growth prospects, but investors should monitor integration, Rytary erosion, valuation, and the new shareholder investigation.
AI Summary
AMRX's Kashiv acquisition could transform it into a higher-margin specialty and biosimilars growth platform, but with valuation already elevated, investors should wait for sustained positive free cash flow, deleveraging, and tangible launch milestones before underwriting the upside.
Description
Amneal Pharmaceuticals is a manufacturer and distributor of generic and specialty medicines, operating three reporting segments: Generics, Specialty and AvKARE. Its Generics business produces a broad range of dosage forms while the Specialty unit markets branded therapies across several therapeutic areas; AvKARE supplies pharmaceuticals, medical and surgical products, and packaging services primarily to government and institutional customers. The company sells through wholesalers, hospitals and pharmacies, and maintains operations in the United States, India, Ireland and other international markets; it is headquartered in Bridgewater, New Jersey and was founded in 2002.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 3 | Aug 10 | AMRX | Amneal Pharmaceuticals, Inc. | Multiple fresh catalysts: Q2 2026 revenue of $796M and adjusted EBITDA of $206M beat estimates, full-year 2026 guidance was raised again, July debt repricing lowers interest costs, and recent FDA approvals add product momentum. Stock is up about 10.5% over 21 trading days. | Closed | -5.1% |
| Jun 9 | Jun 16 | AMRX | Amneal Pharmaceuticals, Inc. | Positive catalyst stack with FDA approval of romidepsin injection solution including 180 days of exclusivity, solid Q1 2026 revenue/adjusted EBITDA, reaffirmed higher full-year guidance, and a 14% 21-day stock uptrend with recent breakout strength. | Closed | +10.6% |